Levocabastine

Source: Wikipedia, the free encyclopedia.
Levocabastine
Clinical data
Trade namesLivostin
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: B3
Routes of
administration
Ophthalmic, intranasal[1]
ATC code
Legal status
Legal status
Identifiers
  • (3S,4R)-1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid
JSmol)
  • Fc1ccc(cc1)[C@]2(CC[C@@H](CC2)N3CC[C@@]([C@H](C)C3)(c4ccccc4)C(O)=O)C#N
  • InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1 checkY
  • Key:ZCGOMHNNNFPNMX-KYTRFIICSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Levocabastine (trade name Livostin or Livocab, depending on the region) is a selective second-generation

Janssen Pharmaceutica in 1979. It is used for allergic conjunctivitis.[3]

As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for the neurotensin receptor NTS2, and was the first drug used to characterise the different neurotensin subtypes.[4][5] This has made it a useful tool for the study of this receptor.[6][7][8][9][10]

The

pharmaceutical drug Bilina is a combination of Levocabastine, benzalkonium chloride, and other components and is typically used in a 0.5 mg/ml suspension as eye-drops, dispensed in 4ml bottles for the treatment of allergic conjunctivitis or similar allergic ocular conditions.[11]

References

  1. ^ "Livostin Nasal Spray". RxMed: Pharmaceutical Information. Retrieved 13 November 2005.
  2. ^ "Livostin - levocabastine hydrochloride suspension". DailyMed. U.S. National Library of Medicine. Retrieved 4 January 2016.
  3. S2CID 8681108
    .
  4. .
  5. .
  6. .
  7. .
  8. .
  9. .
  10. .
  11. ^ "Levocabastine ophthalmic". vademecum.es. Retrieved 11 September 2014.

External links